Topic:

M&A

Latest Headlines

Latest Headlines

Quest buys Summit Health as it aims to restore growth

Quest Diagnostics' revenues fell in the fourth quarter of 2013--a direct violation of its 5-point strategy including "restore growth"--but the company thinks its acquisition of prevention and wellness services outfit Summit Health will help fix those problems.

Aastrom surges after acquiring Sanofi's cell therapies

A little more than a year after reorganizing the company and slashing staff in the wake of a Phase III failure, Ann Arbor, MI-based Aastrom Biosciences has acquired Sanofi's cell therapy and regenerative medicine business for the low, low purchase price of $6.5 million--$4 million payable in cash and $2.5 million in a promissory note.

Bulk up or slim down? Maybe both: Pfizer said to weigh a $100B deal for AstraZeneca

We thought Pfizer was on a diet. After all, CEO Ian Read has garnered investor acclaim for his unit sales and spinoffs, and more of that action is expected. But the U.S.-based drug behemoth reportedly made a $100 billion-plus merger pitch to its struggling rival AstraZeneca. That would be quite a deal to digest.

OPKO buying Israeli inhaler outfit Inspiro Medical

OPKO Health said it has reached an agreement to acquire Inspiro Medical, an Israel-based company that makes an inhaler for the treatment of respiratory diseases.

Say what? Pfizer's $101B buyout pitch to AstraZeneca sparks a megadebate

Pfizer has reportedly made overtures offering to buy the struggling pharma giant AstraZeneca for $101 billion, setting the stage for what could be the first megamatchup in pharma land in years.

Novartis near to wrapping up $1.7B sale of part-owned patchmaker LTS Lohmann

It's been almost a yearlong contest, but a deal for patchmaker LTS Lohmann appears to be nearing the finish line. The private equity firm Nordic Capital is likely to beat out competitor Wendel for the deal, Bloomberg says, at a price of about $1.7 billion.

Pharma's top 10 M&A deals of 2013

All things being relative, 2013 was a pretty good year for M&A in pharma. There were 169 deals valued at $76 billion last year, according to the information ninjas who dice the numbers at...

Report: Surgical device maker Conmed shopping itself around

Surgical device maker Conmed ($CNMD) is said to be putting itself up for sale, ostensibly to avoid trouble from activist shareholders at its annual meeting later this year.

BioAlliance and Topotarget plan to merge, pooling their cancer pipelines

European biotechs BioAlliance Pharma and Topotarget have signed up to join forces, plotting to merge under the former's name and combine their pipelines of late-stage oncology drugs.

Certara buys Synchrogenix with its eye on regulatory writing

Certara, an informatics-focused pharma contractor, has bought up specialty CRO Synchrogenix, absorbing a company devoted to regulatory writing with hopes of expanding its market share.